Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep 25:15:174.
doi: 10.1186/s12883-015-0433-y.

Natalizumab in the pediatric MS population: results of the Italian registry

Angelo Ghezzi  1 , Lucia Moiola  2 , Carlo Pozzilli  3 , Vincenzo Brescia-Morra  4 , Paolo Gallo  5 , Luigi Maria Edoardo Grimaldi  6 , Massimo Filippi  7 , Giancarlo Comi G  8 ; MS Study Group-Italian Society of Neurology
Affiliations

Natalizumab in the pediatric MS population: results of the Italian registry

Angelo Ghezzi et al. BMC Neurol. .

Abstract

Background: Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of patients and after a long-term follow up. Our study was planned to shed lights on this topic.

Methods: A registry was established in 2007 in Italy to collect MS cases treated with Natalizumab (NA) before 18 years of age.

Results: 101 patients were included (69 females), mean age of MS onset 12.9 ± 2.7 years, mean age at NA initiation 14.7 ± 2.4 years. Mean treatment duration was 34.2 ± 18.3 months. During NA treatment, a total of 15 relapses were recorded in 9 patients, annualized relapse rate was 2.3 ± 1.0 in the year prior to NA and decreased to 0.1 ± 0.3 (p < 0.001) at last NA infusion. Mean Expanded Disability Status Scale (EDSS) decreased from 2.6 ± 1.3 at initiation of NA to 1.8 ± 1.2 at the time of last visit (p < 0.001). At brain MRI, new T2 or Gd enhancing lesions were observed in 10/91 patients after 6 months, 6/87 after 12 months, 2/61 after 18 months, 2/68 after 24 months, 3/62 after 30 months, and 5/43 at longer follow up. At the time of last observation, 58% of patients were free from clinical (relapses/increased EDSS) and/or MRI activity (new T2 or gadolinium-enhancing lesions). No relevant adverse events were recorded.

Discussion: NA was safe, well tolerated and very efficacious in the large majority of patients. Our data support the use of this medication in subjects with pediatric MS and an aggressive course.

Conclusions: A relevant reduction of relapse rate and EDSS was observed during NA treatment, compared to pre-treatment period. No evidence of disease activity (NEDA) occurred in 58% of cases.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan-Meyer curves reporting the frequency of patients free from relapses (a), disease progression, defined by an increase of EDSS score at the last observation (b), MRI activity (c), and disease activity (no clinical and/or MRI activity) (d)
See this image and copyright information in PMC

References

    1. Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B. Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol. 2014;13:936–48. doi: 10.1016/S1474-4422(14)70093-6. - DOI - PMC - PubMed
    1. Chitnis T, Tardieu M, Amato MP, Banwell B, Bar-Or A, Ghezzi A, et al. International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology. 2013;80:1161–8. doi: 10.1212/WNL.0b013e318288694e. - DOI - PMC - PubMed
    1. Ghezzi A, Banwell B, Boyko A, Amato MP, Anlar B, Blinkenberg M, et al. The management of multiple sclerosis in children: a European view. Mult Scler. 2010;16:1258–1267. doi: 10.1177/1352458510375568. - DOI - PubMed
    1. Yeh EA, Waubant E, Krupp LB, Ness J, Chitnis T, Kuntz N, et al. Therapies in Pediatric Patients With Refractory Multiple Sclerosis. Arch Neurol. 2011;68:437–444. doi: 10.1001/archneurol.2010.325. - DOI - PubMed
    1. Ghezzi A, Pozzilli C, Grimaldi LM, Brescia Morra V, Bortolon F, Capra R, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology. 2010;75:912–7. doi: 10.1212/WNL.0b013e3181f11daf. - DOI - PubMed